CA3065332A1 - Garcinol compositions for therapeutic management of endoplasmic reticulum stress - Google Patents

Garcinol compositions for therapeutic management of endoplasmic reticulum stress Download PDF

Info

Publication number
CA3065332A1
CA3065332A1 CA3065332A CA3065332A CA3065332A1 CA 3065332 A1 CA3065332 A1 CA 3065332A1 CA 3065332 A CA3065332 A CA 3065332A CA 3065332 A CA3065332 A CA 3065332A CA 3065332 A1 CA3065332 A1 CA 3065332A1
Authority
CA
Canada
Prior art keywords
garcinol
stress
endoplasmic reticulum
reticulum stress
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3065332A
Other languages
English (en)
French (fr)
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Lakshmi MUNDKUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sami Chemicals and Extracts Ltd
Original Assignee
Sami Chemicals and Extracts Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Chemicals and Extracts Ltd filed Critical Sami Chemicals and Extracts Ltd
Publication of CA3065332A1 publication Critical patent/CA3065332A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3065332A 2017-06-22 2018-06-22 Garcinol compositions for therapeutic management of endoplasmic reticulum stress Pending CA3065332A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523592P 2017-06-22 2017-06-22
US62/523,592 2017-06-22
PCT/US2018/038950 WO2018237243A1 (en) 2017-06-22 2018-06-22 Garcinol compositions for therapeutic management of endoplasmic reticulum stress

Publications (1)

Publication Number Publication Date
CA3065332A1 true CA3065332A1 (en) 2018-12-27

Family

ID=64691689

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065332A Pending CA3065332A1 (en) 2017-06-22 2018-06-22 Garcinol compositions for therapeutic management of endoplasmic reticulum stress

Country Status (7)

Country Link
US (1) US20180369166A1 (enExample)
EP (1) EP3614846A4 (enExample)
JP (1) JP2020525425A (enExample)
KR (1) KR20200011492A (enExample)
AU (1) AU2018290320A1 (enExample)
CA (1) CA3065332A1 (enExample)
WO (1) WO2018237243A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317776A (zh) * 2019-07-31 2019-10-11 遵义医学院附属医院 一种内质网应激细胞模型的建立方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111454350B (zh) * 2020-06-01 2020-12-29 广东丸美生物技术股份有限公司 一种重组纤连蛋白突变体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11139965A (ja) * 1997-11-06 1999-05-25 Kikkoman Corp 抗腫瘍薬
JP2000044468A (ja) * 1998-07-29 2000-02-15 Kikkoman Corp リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤
IN2003CH00929A (enExample) * 2003-11-13 2008-10-06
GB0710976D0 (en) * 2007-06-07 2007-07-18 Bioalvo Am Screening method
WO2010036711A1 (en) * 2008-09-23 2010-04-01 Bach Pharma Inc. Methods of modulating protein homeostasis, metabolic syndrome, heavy metal intoxication and nrf2 transcription factors
US20120207744A1 (en) * 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same
EP2461694A4 (en) * 2009-08-06 2013-06-19 Neuraltus Pharmaceuticals Inc TREATMENT OF MACROPHONE-CONDITIONAL DISORDER
EP2581442A4 (en) * 2010-06-14 2013-11-06 Nissan Chemical Ind Ltd METHOD FOR PRODUCING BLOOD-FORMING STEM CELLS
WO2012076988A1 (en) * 2010-12-09 2012-06-14 Indus Biotech Private Limited A complex of garcinol, cyclodextrin and method thereof
DK2658374T3 (en) * 2010-12-30 2016-01-25 Muhammed Majeed Hepatoprotective effect of garcinol
US8329743B2 (en) * 2011-01-10 2012-12-11 Sami Labs Limited Compositions and its use in treating obesity or inducing weight loss
WO2015049553A1 (en) * 2013-10-03 2015-04-09 Delhi Institute Of Pharmaceutical Sciences And Research Effect of garcinol in delaying the progression of diabetic nephropathy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317776A (zh) * 2019-07-31 2019-10-11 遵义医学院附属医院 一种内质网应激细胞模型的建立方法

Also Published As

Publication number Publication date
WO2018237243A1 (en) 2018-12-27
US20180369166A1 (en) 2018-12-27
AU2018290320A1 (en) 2020-02-06
EP3614846A4 (en) 2021-01-13
EP3614846A1 (en) 2020-03-04
KR20200011492A (ko) 2020-02-03
JP2020525425A (ja) 2020-08-27

Similar Documents

Publication Publication Date Title
Wei et al. Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate-incubated HepG2 cells through suppression of the HNF-4α miR122 pathway
Jin et al. Neuroprotective effects of PPAR‐γ agonist rosiglitazone in N171‐82Q mouse model of Huntington's disease
Ni et al. Critical role of FoxO3a in alcohol-induced autophagy and hepatotoxicity
Wang et al. Calcipotriol inhibits NLRP3 signal through YAP1 activation to alleviate cholestatic liver injury and fibrosis
Qiu et al. Effect of sodium butyrate on cell proliferation and cell cycle in porcine intestinal epithelial (IPEC-J2) cells
Mao et al. A polysaccharide extract from the medicinal plant Maidong inhibits the IKK–NF-κB pathway and IL-1β–induced islet inflammation and increases insulin secretion
Liu et al. Emodin alleviates CCl4‑induced liver fibrosis by suppressing epithelial‑mesenchymal transition and transforming growth factor‑β1 in rats
Wang et al. Role of hypoxia-inducible factor-1α in autophagic cell death in microglial cells induced by hypoxia
Yang et al. Sinomenine, a COX-2 inhibitor, induces cell cycle arrest and inhibits growth of human colon carcinoma cells in vitro and in vivo
Kim et al. α-Mangostin ameliorates hepatic steatosis and insulin resistance by inhibition CC chemokine receptor 2
JP7570100B2 (ja) 老化細胞を除去する方法、および老化細胞の調製方法
Wei et al. Indirubin, a small molecular deriving from connectivity map (CMAP) screening, ameliorates obesity-induced metabolic dysfunction by enhancing brown adipose thermogenesis and white adipose browning
Yang et al. Runx3 is a key modulator during the epithelial-mesenchymal transition of alveolar type II cells in animal models of BPD
Cao et al. Sitagliptin reduces endothelial dysfunction and apoptosis induced by high-fat diet and palmitate in thoracic aortas and endothelial cells via ROS-ER stress-CHOP pathway
Zhao et al. Homeobox containing 1 inhibits liver cancer progression by promoting autophagy as well as inhibiting stemness and immune escape
Liang et al. Palmitic acid-induced apoptosis in pancreatic β-cells is increased by liver X receptor agonist and attenuated by eicosapentaenoate
Lu et al. GRP78 silencing enhances hyperoxia-induced alveolar epithelial cell apoptosis via CHOP pathway
Min et al. Effects of Toll-like receptor antagonist 4, 5-dihydro-3-phenyl-5-isoxasole acetic acid on the progression of kidney disease in mice on a high-fat diet
Jiang et al. The effect of hepatic stellate cell derived-IL-11 on hepatocyte injury in hepatic fibrosis
Kuang et al. Dapper1 attenuates hepatic gluconeogenesis and lipogenesis by activating PI3K/Akt signaling
Pinto et al. Unfolded protein response: cause or consequence of lipid and lipoprotein metabolism disturbances?
CA3065332A1 (en) Garcinol compositions for therapeutic management of endoplasmic reticulum stress
Gu et al. A pivotal role of BEX1 in liver progenitor cell expansion in mice
Kalpana et al. Scopoletin intervention in pancreatic endoplasmic reticulum stress induced by lipotoxicity
Ding et al. Lactiplantibacillus plantarum attenuate gossypol-induced hepatic lipotoxicity by altering intestinal microbiota for enriching microbial tryptophan metabolites in Nile tilapia (Oreochromis niloticus)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420

EEER Examination request

Effective date: 20220420